MP78-20 OVERALL SURVIVAL AMONG LOW-RISK PROSTATE CANCER PATIENTS TREATED IN THE VA HEALTH CARE SYSTEM

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History III1 Apr 2014MP78-20 OVERALL SURVIVAL AMONG LOW-RISK PROSTATE CANCER PATIENTS TREATED IN THE VA HEALTH CARE SYSTEM Philip Barbosa, I-Chun Thomas, Benjamin Chung, Sandy Srinivas, Todd Wagner, James Brooks, and John Leppert Philip BarbosaPhilip Barbosa More articles by this author , I-Chun ThomasI-Chun Thomas More articles by this author , Benjamin ChungBenjamin Chung More articles by this author , Sandy SrinivasSandy Srinivas More articles by this author , Todd WagnerTodd Wagner More articles by this author , James BrooksJames Brooks More articles by this author , and John LeppertJohn Leppert More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2503AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Users of the VA health care system (VAHCS) tend to be older and often have comorbid conditions associated with lower baseline health. Studies evaluating outcomes among veterans with prostate cancer, such as the recently published PIVOT trial, demonstrate that veterans suffer from significant competing risks of mortality. A better understanding of overall survival among users of VA health care is critical to inform screening and treatment decisions. We sought to describe patterns of overall survival for all patients treated in the VAHCS with low risk prostate cancer. METHODS We created an analytic cohort of 36,160 patients with low risk prostate cancer, diagnosed at age 75 or less, from the VA Central Cancer Registry (VACCR) diagnosed from 1995-2001. We performed descriptive statistics of patient characteristics (age, race/ethnicity), and exposure history (Agent Orange, tobacco). We created Kaplan-Meier survival estimates to visualize overall survival. RESULTS Mean patient age was 66 years and mean follow-up time was 41 months. 44% of tumors were clinical stage t1c. 22% of patients underwent radical prostatectomy, 26% received primary radiation, and 24.5% were initially treated with androgen deprivation. 2.5% of the cohort had a history of agent orange exposure. Median overall survival of the entire cohort was 73 months. Among patients that received surgery, median overall survival was longer at 89 months (Fig 1a). Overall survival was strongly associated with patient age at diagnosis with a median survival of 87 months for patients diagnosed <50 years, 85 months for 50-60 years, 75 months for 60-70 years, 65 months for 70-80 years. (Fig1b). CONCLUSIONS Overall survival for all patients diagnosed with low risk prostate cancer in the VAHCS is less than general population and single institution reports. These data highlight the importance of population specific life-expectancy estimates in developing high-value prostate cancer screening and treatment decisions. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e929 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Philip Barbosa More articles by this author I-Chun Thomas More articles by this author Benjamin Chung More articles by this author Sandy Srinivas More articles by this author Todd Wagner More articles by this author James Brooks More articles by this author John Leppert More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...